Introduction
JAK3hasemerged asanoncologicdrugtargetforhematologicmalignanciesasw ell ass olid tumors [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . JAK3r egulatest he activity of the anti-apoptotictranscription factors STAT3,S TAT5,a nd AP-1 asw ell ast he anti-apoptoticP I3-K/AKT pathway [9] a nd theirdownstreamtargets (e. g. Cyclin D1) some of whichhavebeen implicated asimportantoncogenicproteins.
WHI-P131( CAS 202475-60-3)i sani nhibitorof JAK3 tyrosine kinase,thatdemonstrated potent in vivo antiinflammatory activity in severalpreclinicalanimalmodels [6, 8, 18] .Weand others haveshownthatWHI-P131 exhibits potentpro-apoptotica nti-canceractivity against humancancercellsw ithconstitutiveJAK3/ STAT3activation [8, 13, 19, 20] a nd displays chemopreventivepropertiesin mousemodelsof colorectalcancer [21] a sw ell asnon-melanomaskin cancer [22] .WHIP131hasafavorable toxicity and pharmacokineticsprofile in animalm odels [23] .WHI-P131wasv ery well tolerated in miceand day30LD 10 valueswerenotreached atparenterald osel evelsashigh as2 50mg/kg [23, 24] .
Liposomaln anoparticle therapeuticscontaining cytotoxica gents mayprovide the foundation forpotentially moreeffectiveand less toxicanti-cancertreatmentstrategiesduetotheirimproved pharmacokinetics,reduced systemictoxicity,and increased intra-tumoral/intra-cellulardelivery [25] [26] [27] .Nanoparticleshavebeen coated
Keyw ords
n Acutel ymphoblastic leukemiac ells n Anti-leukemiaa gent n CAS 202475-60-3 n JAK3tyrosine kinaseinhibitor n WHI-P131,nanoparticle constructs The 30 distinct1 st generation non-LBA NP formulationswere generated withthe thin lipid film hydration method. The LBAcontaining 18 distinctsecond generationNP formulationswere generated using the reversep hasee vaporationm ethod [30] , withthe exception of NP formulation #'s12-14containing TBGS and NP formulation#11 containing DSPE-PEG which werep repared using lipid film hydration ast he liposome preparation method. Fors ome formulationsliteraturem ethods [31] [32] [33] [34] [35] [36] 
Chromatogramsw ereo btained foreachsolution using the sequencesetupo nthe HPLC.The samplesw ereruno nan HP 1100 seriesHPLC using asolvents ystem of 77 %( 0.1 % TFA, 0.1 %TEA)waterand 33 %acetonitrile,areversep hase column,a nd adiode arraydetectors etat3 40nm detection withab and widtho f1 00 nm and areferencewavelengtho f 700 nm withaband widthof100 nm. Aplotof peakareaverses concentrationWHI-P131( mg/mL)wasmade on the Chem. Station Softwaresystem interfaced withthe HPLC.The Calibration equation wasautomaticallycalculated byt he program withaforcethrough the origin tobeY=38079X.Samplesof WHI-P131-free LUV and WHI-P131-loaded LUV wereruno n the HPLC and the concentrationsw ereautomaticallycalculated bythe Chem. Station programusing the abovecalibration curve.
2.3Apoptosisassays
Primary leukemiacells3patients withB-lineage acutelymphoblasticleukemia(ALL)i nrelapseand 3patients withB-lineage CLL wereused in vitro forapoptosisassays undert he exemption category (45 CFR Part 46.101;Category #4:E xisting Data, RecordsReview,a nd Secondary Useo fPathologicS pecimens) in accordancewithDHHS guidelines.Theseprimary cellswere selected becauseo ftheirchemotherapyr esistantprofile as determined byaquantitativef lowcytometrica poptosisassay [37, 38] .Dexamethasone (DEX)wasu sed at50 l g/mL, adriamycin (doxorubicin,A DR)at10 l g/mL, vincristine (VCR), gemcitabine( GEM),methotrexate( MTX),etoposide( ETO), cytarabine (ARA-C)and cladribine (2-CDA)at2 5 l g/mL.In side-by-sidecomparison withthesestandardchemotherapy drugs,W HI-P131-NP wasexamined forits ability toi nduce apoptosisin primary B-lineage ALL cellsatac oncentrationo f 100 l M.
SCID mousexenograftmodel of chemotherapyresistanthumanB-lineage ALL
Female CB.17SCID mice( 6-8 weeksof age) wereo btained from Taconic(Germantown,N Y, USA)and housed in ac ontrolled specific-pathogen-free environment(12-h light-12-h darkphotoperiod;22 -1°C;60% -10%relativehumidity),fully accredited byt he US Departmentof Agriculture. SCID mice werei noculated intravenouslyw ith0.2mLof aleukemicc ell suspensioncontaining 5 · 10 6 RS4;11 cells [39] .One dayafter inoculation of leukemiac ells,miceweretreated withi ntravenous bolus injectionsof eitherv ehicle,100 mg/kg WHI-P131, 0.050mg/kg vincristine or100 mg/kg WHI-P131-NP i. p. for 2consecutivedays.All SCID micewerehoused in microisolator cages(AllentownCaging EquipmentCo.,I nc.,A llentown,N J, USA, orLab Products,I nc.,M aywood,N Y, USA)containing autoclaved food,water,a nd bedding. Trimethoprim-sulfamethoxazole( Bactrim;Roche) wasadded tothe drinking water of the SCID miceo nceaweek. All SCID miceweree lectively killed at121d ays unless theydied orbecame moribund earlier duetotheirdisseminated leukemia.Att he time of theirdeath orkilling,miceweren ecropsied toconfirml eukemia-associated marked hepatomegalyand/ors plenomegaly.Mouse experiments wereapproved byt he ParkerHughesInstitute AnimalCareand UseCommittee (IACUC),a nd all animalcare proceduresconformed tothe Guide fort he Careand Useo f Laboratory Animalsof the NationalResearchCouncil (National AcademyPress,W ashington,D C, 1996). Fort he analysisof the SCID mousexenograftdata, event-free survivaltimesw ere measured from the dayof inoculation of leukemiac ellst othe dayof deatho rkilling. The probability of survivalwasdetermined and the event-free intervalcurvesw ereg enerated using the Kaplan-Meierproductlimitmethod,aspreviouslyreported.
Weused the Mantel-Coxlog-rank test toassess the effects of various treatments on the probability of survivalo fSCID mice inoculated withhumanleukemiacells,asr eported.
3.Results

Physicochemicalcharacterization of 1 st and 2 nd generation NP formulationsof WHI-P131
The first generation of 30 nanoparticle constructs were prepared based on the premisethatt he lipophilicW HI131m olecule would interactw ithand bei ncorporated intothe lipid bilayert hrough hydrophobica nd ionic interactions.However,our efforts toachieveahigh WHI-P131l oadi nthe liposomalNP formulationsby incorporating the drugi ntothe lipid bilayers of the liposomeshavef ailed (Table 1) . Becauseo fthesed isappointing results,asecond generation of NP formulationsw asprepared using the mored ifficultr eversephasee vaporation (RVE)m ethod and anovel water soluble LBA saltof WHI-P131( Table 2 ). The RVE method resulted in significantlyhigherencapsulation of WHI-P131i nside the liposomest hanthe conventional thin layerlipid hydration method,c onsistentw iththe notion thatt he RVE technologyisapreferred technique fort he encapsulation of waters oluble compounds [30] . The establishmentof apHgradientw aschosen asa strategyt otrapWHI-P131i nside the liposomesbased on published entrapmentcharacteristicsof amine compounds [31, 32, 35, 36] .WHI-P131e ncapsulation efficiencies>95% wereachieved in 2 nd generation NP for- (Table 2,T able 3) . Wealsop repared PEGylated nanoparticlesu sing DMPE-PEG, DSPE-PEG and TPGS ast he PEG-derivatized lipid components (Table 2). The presenceo fthesePEG moietiesappeared to limitt he encapsulation of WHI-P131. The maxiumum WHI-P131concentrationst hatcould beachieved in a PEGylated NP werel owert hanthosei nn on-PEGylated versionsof the same NP formulations (Table 2) . However, theseNP formulationshade ncapsulated WHI-P131 concentrationshigherthanthe target10mg/mLconcentration and PEG-derivatized lipidss uchasDSPE-PEG2000 werereported toreducethe immunogenicity of targeted liposomaln anoparticles [29] .Becauseo fo ur futureo bjectiveo fe ngineering multifunctionaltargeted NP formulations,wethus choseNP formulation #11prepared ass tealthyliposomaln anoparticlesw ithDSPE-PEG as the leadf ormulation forbiologictesting.
Invitro and in vivo anti-canceractivity of PEGylated liposomalWHI-P131n anoparticles (WHI-P131-NP)i npreclinicalm odels
Wef irst evaluated the in vitro potencyof WHI-P131-NP against primary leukemicc ellsfrom children withrelapsed B-lineage ALL asw ell asadults withB-lineage The drugsensitivity profilesof primary leukemicc ellsfrom 3patients withrelapsed B-lineage ALL and 3patients withB-lineage CLL were determined using aquantitativef lowcytometrica poptosisassay,a spreviouslydescribed [37] . CLL using quantitativef lowcytometrica poptosisassays.Ass howni nFig. 1and Table 4 ,W HI-P131-NP was capable of causing apoptoticdeathi nl eukemiac ells regardless of theirchemosensitivity orresistanceprofile. The in vivo activity of WHI-P131-NP in aS CID mouse model of chemotherapy-resistantB-lineage ALL [39] wasexamined next.All 15 control micechallenged with ani vinoculumo f5· 10 6 RS4;11 pro-Bleukemiac ells and then received drugsubstance-free vehicle treatments on 2consecutived ays (N=10)o rt he standard chemotherapydrugvincristine (0.050mg/kg,single doseat2 4h post-inoculation) (N=5)e itherdied or werek illed in moribund condition duetotheiradvanced leukemiawithin 65days (mediansurvival: 50days) ( Fig. 2) . Incontrast,the mediansurvivalo f micewas100 days in the test groupthatw eretreated withi .p.i njectionsof WHI-P131-NP (100 mg/kg/ day · 2days)and 4o f1 0micei nthisgroupbecame long-termsurvivors and hadn osignsof overt leukemia (viz.,paraplegiaorhepatosplenomegaly)when they weree lectivelykilled at121days. 
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Discussion
Nakayama etal. recentlyr eported thatconstitutiveactivation of JAK3/STAT5signaling pathwayin B-cell precursors byautocrine IL-7production in the absenceo f BLNK protein,adirectinhibitorof JAK3t hatfunctions asatumors uppressor,c ausesB-precursorleukemiain mice [40] .Inhibition of IL-7r eceptors ignaling orJAK3/ STAT5activity resulted in apoptosisof B-precursorALL cells [40] .Likewise,the JAK3inhibitorWHI-P131was showntoabrogatethe IL-7mediated proliferation and survivalofALL cells [19] .WHI-P131alsoblocksthe proliferation of hematopoieticc ellsw ithactivating JAK3 mutationsand inducesapoptosisin leukemiac ellsw ith constitutivelyactiveJAK-STAT signaling [8, 13] .Our currentstudyprovidesunprecedented evidencethataliposomalNP formulation of WHI-P131triggers apoptosisin primary leukemiac ellsfrom chemotherapy-resistant B-lineage ALL patients.Wef urthers howt hatt he nanotechnology-enabled delivery of WHI-P131e xhibits potentanti-leukemica ctivity in aS CID mousem odel of chemotherapy-resistantB-lineage ALL.Thesef indings demonstratethatJAK3isanattractivem oleculart arget fordisrupting the constitutivelyu pregulated anti-apoptoticS TAT3and STAT5signaling pathwayin cancer cellsu sing nanoparticlesloaded withsmall molecule inhibitors.Futurestudiesw ill focus on developmentof CD19 antigen-specifictargeted anti-leukemicnanoparticles,whichwill beprepared coating our leadliposomal WHI-P131n anoparticle constructr eported herewith anti-CD19 scFvt op repareCD19-directed novel proapoptoticnanoparticlesloaded withWHI-P131. Too ur knowledge,no othert yrosine kinasei nhibitornanoparticleshavee verbeen prepared and thereh avebeen no reported effort topreparetargeted nanoparticlesagainst infantALL.Wep ostulatethatt he nanotechnology-enabled delivery of WHI-P131toleukemiac ellswill significantlybroaden the therapeuticwindowof thispromising newanti-leukemiaa gent.
